
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is a leading global biopharmaceutical company, with a positive outlook due to its diverse portfolio of drugs and vaccines, including its successful immuno-oncology platform led by Keytruda. The recent data from the CADENCE study for Winrevair in Group 2 PH showed exceptional results, and the company's pipeline has a strong catalyst calendar with promising drugs in various stages of development. Additionally, Merck's comprehensive diversity programs and focus on attracting diverse talent should further drive business success. However, there are potential risks to consider, such as unsuccessful commercialization of new growth drivers and generic/biosimilar competition.
Bears say
Merck & Co is expected to experience modest revenue growth in 2026, but this may be surpassed due to management's track record and low expectations. The acquisition of Cidara Therapeutics adds potential peak sales of over $5 billion to MRK's pipeline, and the company's optimization initiative could result in annual savings of $3 billion by the end of 2027, which will be reinvested in strategic growth areas. With a clear win from its CADENCE program and additional growth drivers in the pharmaceutical and vaccine markets, MRK is well-positioned to navigate through LOE in late-2028 and reignite growth in the early-2030s. We anticipate multiple expansion as MRK deploys cash flow into R&D and potential M&A, driving enthusiasm and consensus upgrades over the next 12-18 months.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares